• 134 Citations
  • 6 h-Index
20082019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Ariella Hanker is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 134 Citations
  • 6 h-Index
  • 4 Article
  • 3 Chapter
  • 2 Comment/debate
  • 2 Review article

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., Ericsson, P. G., Lee, K. M., Nixon, M. J., Schwarz, L. J., Sanders, M. E., Dugger, T. C., Cruz, M. R., Behdad, A., Cristofanilli, M., Bardia, A. & 11 others, O’Shaughnessy, J., Nagy, R. J., Lanman, R. B., Solovieff, N., He, W., Miller, M., Su, F., Shyr, Y., Mayer, I. A., Balko, J. M. & Arteaga, C. L., Dec 1 2019, In : Nature communications. 10, 1, 1373.

Research output: Contribution to journalArticle

Open Access
  • 11 Scopus citations

    Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors

    Hanker, A. B., Kaklamani, V. & Arteaga, C. L., Apr 1 2019, In : Cancer discovery. 9, 4, p. 482-491 10 p.

    Research output: Contribution to journalReview article

  • 12 Scopus citations

    Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer (Cancer Research (2017) 77 (3280–3292) DOI: 10.1158/0008-5472.CAN-16-2808)

    Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., Koch, J. P., Gianni, L., Tyson, D. R., Sánchez, V., Rexer, B. N., Sanders, M. E., Zhao, Z., Stricker, T. P. & Arteaga, C. L., Feb 15 2019, In : Cancer Research. 79, 4, 1 p.

    Research output: Contribution to journalComment/debate

    Open Access
  • Correction: HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2(Clin Cancer Res. (2017) 23:15 (4323-4334) DOI: 10.1158/1078-0432.CCR-16-2287)

    Hanker, A. B., Garrett, J. T., Valeria Estrada, M., Moore, P. D., Ericsson, P. G., Koch, J. P., Langley, E., Singh, S., Kim, P. S., Frampton, G. M., Sanford, E., Owens, P., Becker, J., Groseclose, M. R., Castellino, S., Joensuu, H., Huober, J., Brase, J. C., Majjaj, S., Brohee, S. & 6 others, Venet, D., Brown, D., Baselga, J., Piccart, M., Sotiriou, C. & Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

    Research output: Contribution to journalComment/debate

    Open Access
  • Genomic alterations of ERBB receptors in cancer: Clinical implications

    Mishra, R., Hanker, A. B. & Garrett, J. T., Jan 1 2017, In : Oncotarget. 8, 69, p. 114371-114392 22 p.

    Research output: Contribution to journalReview article

    Open Access
  • 32 Scopus citations